Market Currents
More on Baxter (BAX +1%) Q2: net profit rises to $661M from $615M despite forex hurting revenue...
-
Thursday, July 19, 2012, 10:42 AM ETMore on Baxter (BAX +1%) Q2: net profit rises to $661M from $615M despite forex hurting revenue growth. Announces deal with Holland's Sanquin Blood Supply Foundation to support the growth of Baxter's plasma-derived treatments. Guidance: Q3 EPS $1.12-$1.14 vs consensus of $1.16, sales growth of 1% vs. 2%; FY $4.50-$4.56 vs. $4.49-$4.57 prior forecast and $4.52 consensus.
Other date
Latest Earnings Articles
